Navigation Links
BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement

BOTHELL, Wash., Aug. 17 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading manufacturer and marketer of biopreservation tools for cells, tissues, and organs, today announced that it has entered into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based in Vancouver, Canada. STEMCELL Technologies, a member of the StemCell Group of companies, is a leading provider of products that support innovative research in hematology, immunology, cancer research, developmental biology, and many other areas of life science research.

Mike Rice, BioLife's chairman and CEO, noted, "We're very pleased to now have our products represented and distributed throughout the world by STEMCELL Technologies and their sub-distributor partners. Their MethoCult(R) reagent systems have become worldwide standards and we look forward to their distribution network's ability to help our HypoThermosol and CryoStor product platforms achieve the same level of product adoption."

Allen Eaves M.D., Ph.D., founder of STEMCELL Technologies and Chairman of the StemCell Group, commented on the addition of BioLife's products to their reagents and media portfolio by stating, "Our interest in BioLife Solutions has grown as we've seen their products adopted by numerous customers in our strategic markets. We also conducted several comparative cell preservation experiments with CryoStor against other freeze media and were very impressed by the performance of CryoStor in improving post-thaw cell viability and recovery. We feel that the robust regulatory and quality footprint of serum-free and protein-free CryoStor and HypoThermosol will increasingly be valued by researchers and clinicians around the world."

About BioLife Solutions

BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death. Comprehensive small animal intravenous safety studies have been completed on HypoThermosol and CryoStor, and both products are supported by US FDA Master Files. BioLife's enabling technology provides research and clinical organizations significantly enhanced post-preservation cell and tissue viability and function. For more information please visit

About STEMCELL Technologies

STEMCELL Technologies is a life sciences company dedicated to providing a range of products that support innovative research in hematology, immunology, cancer research, developmental biology, and many other areas of life science research. STEMCELL's specialized media and cell separation products are available for a wide range of research applications, and are complemented by a diverse array of cytokines, antibodies, and tissue culture reagents for use in research. Driven by science and enabled by close interactions with global leaders in cell biology and medicine, STEMCELL delivers over 900 products to research scientists in more than 70 countries worldwide. For more information please visit

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    Media Relations:                    Investor Relations:
    Len Hall                            Matt Clawson
    Allen & Caron Inc                   Allen & Caron Inc
    (949) 474-4300                      (949) 474-4300        

SOURCE BioLife Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
2. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
3. Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
4. BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter
5. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
6. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
7. BioLife Solutions Granted European Biopreservation Patent
8. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
9. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
10. BioLife Solutions Credit Facility Increased to $9 Million
11. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier ... models, has promoted Melanie Aregger to serve as Chief Operating Officer. , ... the management team and was promoted to Head of InSphero Diagnostics in ...
(Date:11/24/2015)... 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) ... Pierre Laurin , President and Chief Executive Officer of ... Piper Jaffray 27 th Annual Healthcare Conference to be ... 2015. st , at 8.50am (ET) and ... the day. The presentation will be available live via a ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... YORK , November 24, 2015 ... in a European healthcare ... which the companies will work closely together in identifying European ... unmet medical need. The collaboration is underpinned by a significant ... fund. This is the first investment by Bristol-Myers Squibb in ...
Breaking Biology Technology:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
Breaking Biology News(10 mins):